ArticleJAC-antimicrobial resistance2025
The role of Frailty Index Laboratory in predicting clinical outcomes in patients with
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This retrospective study analysed data from 280 patients diagnosed with CDI, hospitalized at the Policlinic of Bari between 2020 and 2024. Frailty was assessed using FI-Lab, based on 35 routine laboratory tests. Primary outcomes included 14- and 28-day mortality, recurrence during hospitalization and recurrence post-discharge. Associations between FI-Lab and outcomes were evaluated. Results: Of the 280 patients included, 213 survived and 67 died during hospitalization or within 28 days post-infection. Non-survivors had significantly higher FI-Lab scores compared to survivors (0.70 ± 0.15 versus 0.25 ± 0.12, Conclusions: FI-Lab is a predictor of mortality in CDI patients and a valuable tool for early risk stratification. Its utility in predicting recurrences is limited. Prospective studies are warranted to validate these findings and refine therapeutic approaches for high-risk patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.